April 4, 2011
Re: A Message from CSL Behring to Current Vivaglobin® Patients
in the United States
Dear Valued Customer,
In January 2011, CSL Behring announced its intention to discontinue Vivaglobin®
in the United States market by year end. Due to the current delays we are experiencing
in Vivaglobin® supply, we feel it would be disruptive to bring the
product back temporarily, only to discontinue it later this year. Therefore, we
are writing to inform you that CSL Behring has decided to discontinue Vivaglobin®
in the United States effective today.
CSL Behring also manufactures Hizentra®, another innovative subcutaneous
immunoglobulin. Hizentra® is the first and only 20 percent subcutaneous
immunoglobulin (SCIg) in the United States that is indicated as replacement therapy
for patients with primary humoral immunodeficiency. Please visit www.Hizentra.com
to learn more.
If you are a current Vivaglobin® patient or caregiver of a Vivaglobin®
patient, speak with your healthcare provider about Hizentra® or other
immunoglobulin (Ig) therapy options that may be appropriate. To help you make the
transition to Hizentra®, CSL Behring is offering a Hizentra®
sample program. This program is designed to offer Vivaglobin® patients
a one-month supply of Hizentra® to determine if Hizentra®
is right for them. We encourage you to contact IgIQ (1-877-355-IgIQ) for more information.
Please see Important Safety Information for Hizentra® and Vivaglobin®
below, and the enclosed full prescribing information for each product.
Thank you for your continued trust in CSL Behring and in our life-saving therapies.
Senior Vice President
North America Commercial Operations
Click here for information if you are a Health Care Professional.